NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 8 November 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Rada Todd (Chair) Present for all items
2. Dr James Fotheringham (Vice-chair) Present for all items
3. Professor Abdallah Al-Mohammad Present for all items
4. Dr Peter Baker-Gulliver Items 4 to 4.3.2
5. Richard Ballerand Present for all items
6. Dr Craig Buckley Items 4 to 4.3.2
7. Dr Andrew Champion Present for all items
8. Dr Louis Choo Present for all items
9. Dr Justin Daniels Present for all items
10. Dr Fiona MacPherson Smith Items 1 to 4.3.2
11. Professor G.J. Melendez-Torres Items 5 to 5.2.2
12. Stephen O’Brien Present for all items
13. Becky Pennington Items 1 to 4.3.2
14. Dominic Pivonka Items 5 to 5.2.2
15. Dr Mohit Sharma Present for all items
16. Alan Thomas Present for all items
17. Min Ven Teo Present for all items

NICE staff (key players) present

Richard Diaz, Associate Director Items 1 to 4.3.2

Henry Edwards, Associate Director Items 5 to 5.2.2

Daniel Davies, Project Manager Items 1 to 4.3.2

Jeremy Powell, Project Manager Items 5 to 5.2.2

Yelan Guo, Heath Technology Assessment Adviser Items 1 to 4.3.2

Carl Prescott, Heath Technology Assessment Adviser Items 5 to 5.2.2

Harsimran Sarpal, Heath Technology Assessment Analyst Items 1 to 4.3.2

Owen Harrison, Heath Technology Assessment Analyst Items 5 to 5.2.2

Adam Storrow, Business Analyst, RIA Items 4.2.1 to 5.2.2

Olivia Waring, Senior Medical Editor Items 1 to 4.1.3

Ruth Melville, Senior Medical Editor Items 5 to 5.2.2

Mandy Tonkinson, Public Involvement Adviser, PIP Items 1 to 4.1.3

Laura Kelly, Assistant Project Manager, COT Items 1 to 4.1.3 & 5 to 5.1.3

Lyn Davis, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Wajeeha Asim, Administrator, TA Items 1 to 4.3.2

Rumana Zaman, Administrator, TA Items 5 to 5.2.2

NICE staff (observers) present

Sarah Wilkes, Technical Analyst, Commercial Liaison team Items 5 to 5.2.2

Stephen Norton, Technical Analyst, Managed Access Items 5 to 5.2.2

Carl Jackson, Assistant Project Manager, COT Items 1 to 4.3.2 & 5.1.3 to 5.2.2

Liam Murray. Administrator, COT Items 1 to 4.3.2

External assessment group representatives present

G.J. Melendez-Torres, Peninsula Technology Assessment Group (Pen-TAG), Items 1 to 4.2.1

Madhu Muthukumar, Peninsula Technology Assessment Group (Pen-TAG), Items 1 to 4.2.1

Nigel Armstrong, Centre for Reviews and Dissemination and Centre for Health Economics -York, Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Dr David Jackson, Consultant Physician; Head, Guy’s Severe Asthma Centre; Reader in Respiratory Medicine, clinical expert nominated by AstraZeneca, Items 1 to 4.1.3

Olivia Fulton, Patient expert nominated by Asthma + Lung UK, Items 1 to 4.1.3

Anne Little, Patient expert nominated by Asthma + Lung UK, Items 1 to 4.1.3

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 5 to 5.2.2

Dave Chuter, Patient expert nominated by Guts UK, Items 5 to 5.1.3

Professor Wasat Mansoor, Consultant in Medical Oncology, Clinical expert nominated by BMS, Items 5 to 5.1.3

Dr Elizabeth Smyth, Consultant in Gastrointestinal Oncology Clinical expert nominated by Royal College of Physicians, Items 5 to 5.1.3

Helen West, Patient expert nominated by Guts UK, Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Radha Todd welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 11 October 2022

### Appraisal of tezepelumab for treating severe asthma [ID3910]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca UK Ltd.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor Abdallah Al-Mohammad declared an indirect financial interest in that he has attended an advisory board with AstraZeneca for a different agent and different indication (Dapagliflozin the treatment of heart failure with preserved ejection fraction) in September 2022. It was agreed that his declaration would not prevent Professor Al-Mohammad from participating in discussions on this appraisal.
* Nominated patient expert Olivia Fulton declared direct non-financial interests as she sits on the Astra Zeneca Patient Partnership Program but has not been involved in any work regarding this appraisal. It was agreed that her declaration would not prevent Olivia from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Abdallah Al-Mohammad, Dr Mohit Sharma, and Alan Thomas.
  1. Part 2a – Closed session (experts, company representatives and members of the public, were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10796>

### Appraisal of nivolumab in combination for untreated advanced unresectable recurrent or metastatic oesophageal squamous cell carcinoma cancer [ID2712]

* 1. Part 1 – Open session
     1. The chair Dr Radha Todd welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Bristol-Myers Squibb.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee Chair Dr Radha Todd declared a direct financial interest, as she had been a member of a Pfizer advisory board between September and November 2021. It was agreed that this declaration would not prevent Dr Todd from chairing and participating on this appraisal from participating in this discussion
* Nominated clinical expert Dr Elizabeth Smyth declared direct non-financial interests as she is co-chair of the EORTC (European Organisation for Research and Treatment of Cancer) Gastric Cancer Taskforce and member of the ESMO Guidelines Committee and Senior author of the Gastric and Oesophageal guidelines. It was agreed that her declarations would not prevent Dr Smyth from providing expert advice to the committee.
* Nominated clinical expert Dr Wasat Mansoor declared direct financial interests as he has received payments for being on advisory boards for BMS & MSD. it was agreed his declaration would not prevent Dr Mansoor from providing expert advice to the committee.
  + 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Henry Edwards.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10572>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 13 December and will start promptly at 09.30.